Atorvastatin: a potential chemopreventive agent in bladder cancer (Q40339220)

19 September 2017

Atorvastatin: a potential chemopreventive agent in bladder cancer (English)

1 reference

19 September 2017

Ashish M Kamat

1

1 reference

PubMed ID

16360444

19 September 2017

Gina M Nelkin

series ordinal

2

1 reference

PubMed ID

16360444

19 September 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

19 September 2017

1 reference

19 September 2017

66

1 reference

19 September 2017

6

1 reference

19 September 2017

1209-1212

1 reference

Smoking and Cancer of the Lower Urinary Tract

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Long-Term Epidemiologic Prediction of Coronary Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Passive cigarette smoking and reduced HDL cholesterol levels in children with high-risk lipid profiles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Low total cholesterol is associated with high total mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Carcinogenicity of lipid-lowering drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Thymidine incorporation is highly predictive of colony formation and can be used for high-throughput screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Statin use and cancer risk in the General Practice Research Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Hyperlipidaemia is positively correlated with lymph node metastasis in men with early gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Comparative effects of lipid-lowering therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Role of endothelial dysfunction in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Review Article: The Role of Ras Superfamily Proteins in Bladder Cancer Progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

Reclassification of simvastatin to over-the-counter status in the United Kingdom: a primary prevention strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.06.075

10.1016/J.UROLOGY.2005.06.075

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference

PubMed ID

16360444